Shijiazhuang Yiling Pharmaceutical Co., Ltd. Class A
SSZSE:00260315.65
CNY
+0.54
(+3.57%)
ISIN
CNE1000015S0
Return %
Stock
S&P 500
1Y
-9.33
13.14
3Y
-26.66
80.78
5Y
-3.57
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Chun Xia
- Full Time Employees
- 11,343
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- No. 238 Tianshan Street Shijiazhuang HE China 050035
- IPO Date
- Jul 18, 2011
- Website
- yiling.cn
- Similar Companies
- Business
- Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) engages in the research, development, production, and sale of patented traditional Chinese medicines, chemical and biological pharmaceuticals, and healthcare products primarily in China with exports to over 30 countries including Nigeria, Canada, South Korea, Russia, and Vietnam. Founded in 1992 by Professor Wu Yiling of the China Academy of Engineering and headquartered at No. 238 Tianshan Street, Shijiazhuang, China, the company operates through segments including patented TCM, medicinal chemistry, and health industry products; it listed on the Shenzhen Stock Exchange in 2011 and employs over 16,000 people across multiple global subsidiaries. Core products encompass patented innovative TCM formulations such as Tongxinluo Capsules for cardiovascular protection via lipid regulation, anti-inflammation, and anticoagulation; Shensong Yangxin Capsules for arrhythmias including premature beats, paroxysmal atrial fibrillation, and bradycardia; Qiangxin Capsules (rhizoma ligustici wallichii fumi capsules) for chronic heart failure; Lianhua Qingwen Capsules and Lianhua Cough Tablets for influenza, colds, and respiratory infections; Jinlida Granules for diabetes; Tongluo Mingmu Capsules for diabetic retinopathy; along with Western generics like Celecoxib Capsules (50mg, 100mg, 200mg, 400mg) for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and dysmenorrhea; Acyclovir Tablets and Capsules (200mg, 400mg, 800mg) for herpes zoster, genital herpes, and chickenpox; Ciprofloxacin Tablets (250mg, 500mg) for skin infections, bone/joint issues, urinary tract infections, and more; Felodipine for hypertension; dietary supplements, health foods, formula granules, disinfection products, and personal protective equipment. Recent developments include international regulatory approvals such as Shensong Yangxin Capsule registration as a herbal medicine in Nigeria in October 2023 and ongoing registrations in over 50 countries for products like Tongxinluo and Lianhua Qingwen Capsules; sustained R&D investment at around 10-15% of revenue supporting over 150 patents and new formulations; expansion of chemical & bio-medicines via contract manufacturing (CMO), dual domestic/international generic drug registrations targeting high-barrier markets in Europe and the US, and new API production at Wanyang Hengshui Pharmaceutical site compliant with US FDA and EU cGMP for cardiovascular, respiratory, oncology, and antiviral APIs; strategic digital health content partnerships announced in August 2025; alongside a 2024 annual report reflecting operating revenue of 6.51 billion yuan amid market challenges, no dividend payout, and focus on capacity optimization recovering over 10 billion yuan in cash.